CA2256633C - Selected derivatives of k-252a - Google Patents

Selected derivatives of k-252a Download PDF

Info

Publication number
CA2256633C
CA2256633C CA002256633A CA2256633A CA2256633C CA 2256633 C CA2256633 C CA 2256633C CA 002256633 A CA002256633 A CA 002256633A CA 2256633 A CA2256633 A CA 2256633A CA 2256633 C CA2256633 C CA 2256633C
Authority
CA
Canada
Prior art keywords
compound
hydrogen
mmol
lower alkyl
fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002256633A
Other languages
English (en)
French (fr)
Other versions
CA2256633A1 (en
Inventor
Robert L. Hudkins
John P. Mallamo
Masami Hamano
Reiko Tanaka
Chikara Murakata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of CA2256633A1 publication Critical patent/CA2256633A1/en
Application granted granted Critical
Publication of CA2256633C publication Critical patent/CA2256633C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
CA002256633A 1996-06-03 1997-06-02 Selected derivatives of k-252a Expired - Fee Related CA2256633C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65736696A 1996-06-03 1996-06-03
US08/657,366 1996-06-03
PCT/US1997/009448 WO1997046565A1 (en) 1996-06-03 1997-06-02 SELECTED DERIVATIVES OF K-252a

Publications (2)

Publication Number Publication Date
CA2256633A1 CA2256633A1 (en) 1997-12-11
CA2256633C true CA2256633C (en) 2009-04-07

Family

ID=24636859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002256633A Expired - Fee Related CA2256633C (en) 1996-06-03 1997-06-02 Selected derivatives of k-252a

Country Status (17)

Country Link
US (1) US6306849B1 (enExample)
EP (1) EP0918777B1 (enExample)
JP (1) JP2000511902A (enExample)
CN (1) CN1198827C (enExample)
AT (1) ATE222912T1 (enExample)
AU (1) AU716656B2 (enExample)
BR (1) BR9711093A (enExample)
CA (1) CA2256633C (enExample)
DE (1) DE69715010T2 (enExample)
DK (1) DK0918777T3 (enExample)
ES (1) ES2183184T3 (enExample)
NO (1) NO312464B1 (enExample)
NZ (2) NZ333018A (enExample)
PT (1) PT918777E (enExample)
RU (1) RU2205184C2 (enExample)
UA (1) UA67725C2 (enExample)
WO (1) WO1997046565A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
WO2000018407A1 (en) 1998-09-25 2000-04-06 Cephalon, Inc. Methods for preventing/treating damage to sensory hair cells and cochlear neurons
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
EP1545615A4 (en) * 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI2270048T1 (sl) * 2002-12-24 2016-01-29 Rinat Neuroscience Corp. Protitelesa proti NGF-ju in postopki uporabe le-teh
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7655231B2 (en) * 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
SG152226A1 (en) * 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
KR101431165B1 (ko) * 2008-12-22 2014-08-18 크레아빌리스 에스.에이. 인돌로카르바졸 화합물의 중합체 컨쥬케이트의 합성

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554402A (en) 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
EP0303697B1 (en) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
WO1991009034A1 (en) 1989-12-14 1991-06-27 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
JPH0586068A (ja) 1991-03-04 1993-04-06 Rikagaku Kenkyusho 新規抗生物質ｒｋ−１４０９、その製造法並びに抗腫瘍剤及び抗炎症剤
CA2123096A1 (en) 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
JP2593021B2 (ja) 1991-12-13 1997-03-19 伊藤ハム株式会社 ウシ胚の性の識別方法
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
ES2136103T3 (es) 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
JPH0673063A (ja) 1992-06-22 1994-03-15 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１誘導体
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
CA2123895A1 (en) * 1992-09-21 1994-03-31 Tatsuya Tamaoki A therapeutic agent for thrombocytopenia
DE69409641T2 (de) 1993-05-28 1998-11-26 Cephalon, Inc., West Chester, Pa. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
WO1995000520A1 (en) 1993-06-17 1995-01-05 Ciba-Geigy Ag Indolocarbazole compound useful as proteinkinase c inhibitor
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
BR9711093A (pt) 1999-08-17
ES2183184T3 (es) 2003-03-16
EP0918777A1 (en) 1999-06-02
DK0918777T3 (da) 2002-12-30
PT918777E (pt) 2003-01-31
NZ333018A (en) 2000-05-26
CA2256633A1 (en) 1997-12-11
JP2000511902A (ja) 2000-09-12
UA67725C2 (en) 2004-07-15
NO312464B1 (no) 2002-05-13
NO985622L (no) 1999-02-02
AU716656B2 (en) 2000-03-02
NO985622D0 (no) 1998-12-02
DE69715010D1 (de) 2002-10-02
HK1018703A1 (en) 1999-12-30
WO1997046565A1 (en) 1997-12-11
ATE222912T1 (de) 2002-09-15
NZ504097A (en) 2005-06-24
RU2205184C2 (ru) 2003-05-27
CN1198827C (zh) 2005-04-27
AU3225397A (en) 1998-01-05
CN1226893A (zh) 1999-08-25
DE69715010T2 (de) 2003-04-03
EP0918777B1 (en) 2002-08-28
US6306849B1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
CA2256633C (en) Selected derivatives of k-252a
EP0354583B1 (en) DC-88A derivatives
KR102064807B1 (ko) 바이러스 감염을 치료하기 위한 피페리디노-피리미딘 유도체
KR930009357B1 (ko) 수용성 캠프토테신 유도체 및 이의 제조방법
JP6898336B2 (ja) Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用
US20210292340A1 (en) Cell necrosis inhibitor, preparation method therefor and use thereof
JP3023990B2 (ja) カンプトテシン誘導体及びその製造方法
CZ283281B6 (cs) Způsob přípravy v poloze 5 substituovaných pyrrolo(2,3-d)pyrimidinů
US4075339A (en) Biologically active compounds
US6268375B1 (en) 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
DK173952B1 (da) Anvendelse af spergualinderivater til fremstilling af lægemidler med immunosuppressiv virkning
CN115417877B (zh) 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用
DK156831B (da) Bis-dioxopiperazin-derivater med antitumor-aktivitet og farmaceutisk acceptable salte deraf
EP0333176B1 (en) Substituted benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
CN109369623A (zh) 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用
CN113816959A (zh) 一种以恩诺沙星为原料制备的异白叶藤碱类似物及其制备方法和应用
EP4644391A1 (en) Novel phenylquinolone compound having antibacterial and anticancer functions, and preparation thereof
US6875865B1 (en) Selected derivatives of K-252a
KR100485997B1 (ko) K-252의선택된유도체
CN107382944B (zh) 一类具有抗肿瘤活性的香豆素棉酚衍生物及其合成方法
EP0191375A2 (en) 7-n-aminomethylenemitomycin derivatives, process for production thereof and anti-tumor composition
PL188075B1 (pl) Rozpuszczalne w wodzie C-pierścieniowe analogi 20(S)-kamptotecyny, kompozycja farmaceutyczna zawierająca te związki, ich zastosowanie oraz sposób wytwarzania
HK1018703B (en) Selected derivatives of k-252a
CN113816976A (zh) 一种以莫西沙星为原料制备的异白叶藤碱类似物及其制备方法和应用
JPH05306284A (ja) インドロキノリン誘導体

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130604